Reading good review articles can shape ideas, help connecting the dots and understanding what’s coming ahead in science. Here’s 10 review articles that helped me shape my views on breast oncology and drug development:

🚨🔥Hot off the press🔥 Our study on the impact of radiation to host immune structures during chemoradiation > durva in patients with st.III non small cell lung cancer is out in Frontiers - Oncology #nsclc 🫁⚡️ 🧵 1/5 frontiersin.org/articles/10.33…

Practice guidelines : SBRT & ultra central lung tumors 🫁 - excellent local control ✨ - 👍 selected patient populations - ⚠️ risk of severe toxicity ⚠️ - consider non-SBRT schedules in case of endobronchial tumors / anticoagulation use OncoAlert sciencedirect.com/science/articl…

TMT should be offered to ALL patients that have solitary <7cm T2 muscle invasive Bladder Cancer. #uroonco23 GETUG Paul Sargos GU Cast | Urology podcast!

Chers futurs internes: on vous donne rendez-vous ce vendredi à 20h pour vous parler de l'oncologie médicale et l'oncologie radiothérapie avec la SFjRO !

Safety of T-DM1 with concurrent #radiotherapy : a systematic review and meta-analysis Part of the ESTRO consensus statements on RT and drug integration for #BreastCancer OncoAlert #OncoAlert Final link after proofing at: sciencedirect.com/science/articl…

🎙Study on safety of combining RT with trastuzumab emtansine (T-DM1) for #breastcancer @oncoalert Radiotherapy & Oncology 📌Part of ESTRO recommendations SR & MA ➡️9📝included 📊RESULTS: 👉⬆️ grade 3+ 🧠radionecrosis (17%) 👉very ⬇️ grade 3+ radiation-related 🫁pneumonitis (<1%)

Gustave Roussy is now equipped with a new #FLASH #radiotherapy system by #THERYQ. The first of it's kind in France, this marks a key step in our goal to deliver advanced treatments for our patients & provide prospective clinical evidence for ultra-high dose rate radiotherapy.

Shekinah Elmore, MD, MPH Having struggled to open a door, so holding it open for those coming behind you.

📣ISRS guidelines on the management of radiation necrosis 🧠 ✨ Symptomatic steroid refractory brain RN : 📍Bevacizumab in select patients is recommended 📍Consider surgery if symptomatic despite non-invasive treatments OncoAlert #OncoAlertAF ➡️📖 redjournal.org/article/S0360-…

✨Prostate cancer & RT ✨ 🚨GFRU consensus delineation guidelines : pelvic lymph node CTV🚨 OncoAlert #OncoAlertAF ➡️📖 redjournal.org/article/S0360-…

Hey Nicolas Benziane-Ouaritini, first page in the latest edition of European Urology Oncology. 🤘🤘🤘🤘🤘🤘🤘🤘🤘🤘🤘 🕸️🕸️SPIDER STUDY🕸️🕸️ 🕷️Dose escalation in the salvage setting must be reevaluated, integrating modern imaging, in a prospective trial. Supiot Stéphane

First 🇨🇭 oesophageal cancer patient enrolled into randomized PROTECT trial, comparing neoadjuvant Photon or Proton radiochemotherapy 👉 Strong collaboration between PSI Paul Scherrer Institut and Unispital_USZ Radio-Onkologie USZ Comprehensive Cancer Center Zurich psi.ch/de/media/forsc…

Consensus Delineation Guidelines for Pelvic Lymph Node Radiation Therapy of Prostate Cancer: On Behalf of the Francophone Group of Urological Radiation Therapy (GFRU) ⁦Paul Sargos⁩ ⁦Supiot Stéphane⁩ ⁦Vérane Achard⁩ sciencedirect.com/science/articl…

So honoured to have been part of the PACE team for the last 12 years. I have learned so much from Nicholas van As Prof Emma Hall and the whole team. Thanks to the 874 men and over 30 hospitals who partnered with us and to Accuray for funding. Abstract here astro2023.eventscribe.net/index.asp?sess…

📣ASTRO 2023 : FASTRACK II ▶️SBRT & renal cell cancer ▶️multicenter phase 2 ▪️mostly T1b+ ▪️26Gy (1F) or 42Gy in 3F if >4cm 👍10% grade 3 tox & no grade 4/5 ✔️LC 100% throughout the lifetime of trial 〰️ 1-year OS 99% & 3-years 82% OncoAlert #OncoAlertAF cdmcd.co/LEmmGQ

Docteurs Juniors en oncologie medicale: bilan de la première promotion très positif ! Très largement grâce à l'implication des services ++ Quelques pistes d'améliorations pour faire encore mieux : ->authors.elsevier.com/c/1hwOK1iV7zLaP Laune Quentin Société Française du Cancer

🎙️ Oligoprogression in 👥 w/ metastatic #NSCLC could be effectively treated w/ SBRT ➕SOC‼️@oncoalert The Lancet 📌Ph 2, RCT - SBRT in oligoprogressive metastatic breast cancer or NSCLC - Oligoprogression ≤5 lesions on PET-CT or CT - 1:1 Random to SOC vs. SBRT + SOC 📊RESULTs

Please tweete the good stuff Alison. The room was full 10 minutes prior to the session… ESTRO prostate cancer is a popular topic, we need bigger rooms… #ESTRO24

IMN2 study shows DM and OS improvement with IMN RT in era of modern chemotherapy . CT based planning showed no difference in cardiac mortality #estro24 ⁦Icro Meattini⁩